These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 34380640)

  • 1. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.
    Khouri IF; Milton DR; Gulbis AM; Jabbour EJ; Nastoupil L; Ledesma C; Anderlini P; Bashir Q; Daher M; Im JS; Iyer SP; Marin D; Mehta RS; Olson AL; Popat UR; Qazilbash M; Saini N; Samaniego F; Rondon G; Medeiros LJ; Champlin RE
    Clin Cancer Res; 2021 Nov; 27(21):5847-5856. PubMed ID: 34380640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
    Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
    Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
    J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
    Fung HC; Cohen S; Rodriguez R; Smith D; Krishnan A; Somlo G; Sahebi F; Senitzer D; O'Donnell MR; Stein A; Snyder DS; Spielberger R; Bhatia R; Falk P; Molina A; Nademanee A; Parker P; Kogut N; Popplewell L; Vora N; Margolin K; Forman SJ
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):649-56. PubMed ID: 14569561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
    Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
    Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
    Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
    Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
    Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.
    Robinson SP; Boumendil A; Finel H; Blaise D; Poiré X; Nicolas-Virelizier E; Or R; Malladi R; Corby A; Fornecker L; Caballero D; Pohlreich D; Nagler A; Thieblemont C; Finke J; Bachy E; Vincent L; Schroyens W; Schouten H; Dreger P
    Bone Marrow Transplant; 2016 Mar; 51(3):365-71. PubMed ID: 26618550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
    Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.
    Holstein SA; Suman VJ; Owzar K; Santo K; Benson DM; Shea TC; Martin T; Silverman M; Isola L; Vij R; Cheson BD; Linker C; Anderson KC; Richardson PG; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1414-1424. PubMed ID: 32325171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
    Robinson S; Dreger P; Caballero D; Corradini P; Geisler C; Ghielmini M; Le Gouill S; Kimby E; Rule S; Vitolo U; Dreyling M; Hermine O;
    Leukemia; 2015 Feb; 29(2):464-73. PubMed ID: 25034148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogenic stem cell transplantation as salvage therapy for patients relapsing after autologous transplantation: experience from a single institution.
    Martínez C; Carreras E; Rovira M; Urbano-Ispizua A; Esteve J; Fernández-Avilés F; Perales M; Rives S; Gómez M; Montserrat E
    Leuk Res; 2001 May; 25(5):379-84. PubMed ID: 11301105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
    Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia.
    Martino R; Bellido M; Brunet S; Sureda A; Peyret M; Guárdia R; Altés A; Domingo-Albós A; Sierra J
    Bone Marrow Transplant; 1998 May; 21(10):1023-7. PubMed ID: 9632276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.
    Martínez C; Carreras E; Rovira M; Urbano-Ispizua A; Esteve J; Perales M; Fernández F; Montserrat E
    Bone Marrow Transplant; 2000 Sep; 26(6):677-9. PubMed ID: 11035375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin's disease following autologous stem cell transplantation.
    Ruiz-Argüelles GJ; López-Martínez B; López-Ariza B
    Arch Med Res; 2003; 34(3):242-5. PubMed ID: 14567405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.